Reviewed 10 November 2026 for medical education. This material is not a prescribing protocol; apply local clinical guidance and individual assessment.
Overview
Uterotonics contract uterine smooth muscle, principally to prevent or manage postpartum haemorrhage (PPH) from uterine atony. Choice reflects evidence, availability, contraindications, cold-chain constraints and whether the aim is prevention or treatment [1–3].
Correct drug classification
- Oxytocin: peptide oxytocin-receptor agonist (Gq/PLC/IP3-calcium signaling).
- Carbetocin: longer-acting synthetic oxytocin analogue used for PPH prevention where indicated.
- Ergometrine/methylergometrine: ergot alkaloid uterotonics; strong sustained contractions and vasoconstriction.
- Misoprostol: prostaglandin E1 analogue; heat-stable and administered by several routes.
- Carboprost: prostaglandin F2-alpha analogue for refractory uterine atony in suitable patients.
Desmopressin is an antidiuretic V2-receptor agonist, not a uterotonic; atosiban is a uterine relaxant and labetalol an antihypertensive, not uterotonics [1].
Prevention
WHO 2025 recommends a quality-assured uterotonic to prevent PPH at all births: oxytocin 10 IU IM/IV is recommended, with carbetocin or misoprostol alternatives depending on context and availability. Prevention protocols should not routinely stack multiple prophylactic uterotonics without an indication [2].
Recognition and first response
PPH requires rapid objective blood-loss assessment and action. WHO first-response care comprises uterine massage, an oxytocic, tranexamic acid, intravenous fluids, genital-tract examination and escalation or transfer. Tranexamic acid is an antifibrinolytic, not a uterotonic. Treat suspected hemorrhage promptly rather than waiting for laboratory confirmation [2,3].
Treatment and pharmacologic safeguards
IV oxytocin is recommended for PPH treatment. If unavailable or ineffective, WHO includes selected ergometrine combinations or prostaglandin options, including sublingual misoprostol 800 micrograms, within escalation care [3]. Ergometrine is generally avoided in hypertension/preeclampsia because of vasoconstriction. Carboprost is generally avoided in asthma because of bronchospasm risk. Misoprostol causes shivering, fever and diarrhea. Oxytocin infusion needs monitoring for fluid effects, hypotension with rapid IV administration and excessive uterine activity in intrapartum use [1–3].
Conclusion
Uterotonic agents do not replace assessment for trauma, tissue retention or coagulopathy. Appropriate technique, rapid team escalation and access to blood products and procedural care remain essential [2,3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage. Geneva: WHO; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK619233/table/ch3.tab7/
- World Health Organization. Consolidated guidelines for the prevention, diagnosis and treatment of postpartum haemorrhage: first-response treatment. Available from: https://www.ncbi.nlm.nih.gov/books/NBK619233/table/ch3.tab33/
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.